AT159426T - A process for producing a solid dispersion - Google Patents

A process for producing a solid dispersion

Info

Publication number
AT159426T
AT159426T AT92907654T AT92907654T AT159426T AT 159426 T AT159426 T AT 159426T AT 92907654 T AT92907654 T AT 92907654T AT 92907654 T AT92907654 T AT 92907654T AT 159426 T AT159426 T AT 159426T
Authority
AT
Austria
Prior art keywords
producing
process
solid dispersion
dispersion
solid
Prior art date
Application number
AT92907654T
Other languages
German (de)
Inventor
Kouichi Nakamichi
Shougo Izumi
Hiroyuki Yasuura
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to JP11255491 priority Critical
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AT159426T publication Critical patent/AT159426T/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14589572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT159426(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/937Dispersion or emulsion
AT92907654T 1991-04-16 1992-04-14 A process for producing a solid dispersion AT159426T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11255491 1991-04-16

Publications (1)

Publication Number Publication Date
AT159426T true AT159426T (en) 1997-11-15

Family

ID=14589572

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92907654T AT159426T (en) 1991-04-16 1992-04-14 A process for producing a solid dispersion

Country Status (12)

Country Link
US (1) US5456923A (en)
EP (1) EP0580860B2 (en)
JP (1) JP2527107B2 (en)
KR (1) KR182801B1 (en)
AT (1) AT159426T (en)
AU (1) AU1537292A (en)
CA (1) CA2108575C (en)
DE (2) DE69222847D1 (en)
DK (1) DK0580860T4 (en)
ES (1) ES2111065T5 (en)
GR (1) GR3025864T3 (en)
WO (1) WO1992018106A1 (en)

Families Citing this family (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
AU671811B2 (en) 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
WO1994008561A1 (en) * 1992-10-14 1994-04-28 Nippon Shinyaku Co., Ltd. Crystalline condition dislocating method
JP2616252B2 (en) * 1992-10-16 1997-06-04 日本新薬株式会社 Preparation of the wax matrix
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US6312726B1 (en) * 1993-08-20 2001-11-06 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
EP0729748B1 (en) * 1993-11-18 2003-02-26 Nippon Shinyaku Company, Limited Process for producing stable medicinal composition
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DK0797987T3 (en) * 1994-12-19 2004-02-16 Daiichi Seiyaku Co Granular preparation having sustained release and process for production thereof
DE19509807A1 (en) * 1995-03-21 1996-09-26 Basf Ag A process for the preparation of drug formulations in the form of a solid solution of the active ingredient in a polymer matrix, with this method produced active substance preparations
BE1009856A5 (en) * 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
PT784974E (en) * 1995-07-26 2003-09-30 Kyowa Hakko Kogyo Kk Preparation of xantin derivatives in a solid dispersion
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE69726729T2 (en) * 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungicidal agents with improved bioavailability
US6139872A (en) * 1996-08-14 2000-10-31 Henkel Corporation Method of producing a vitamin product
JPH10114682A (en) * 1996-10-11 1998-05-06 Shimizu Kagaku Kk Sustained release medicine mixed with clucomannan for internal use
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
DK0901786T3 (en) 1997-08-11 2007-10-08 Pfizer Prod Inc Solid pharmaceutical dispersions possess increased bioavailability
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
HN1998000115A (en) * 1997-08-21 1999-06-02 Warner Lambert Co Dosificacin forms farmacuticas slidas
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
WO1999034780A1 (en) * 1998-01-12 1999-07-15 Bühler AG Method and device for capsulating active ingredients
US7300667B1 (en) 1999-05-27 2007-11-27 Euro-Celtique, S.A. Preparations for the application of anti-inflammatory, especially antiseptic agents and/or agents promoting the healing of wounds, to the lower respiratory tract
US7297344B1 (en) 1999-05-27 2007-11-20 Euro-Celtique, S.A. Preparations for the promotion of wound healing in the upper respiratory tract and/or ear
ES2260915T3 (en) * 1998-05-27 2006-11-01 Euro-Celtique S.A. Preparations for application of antiinflammatory agentets, especially antiseptic agents and / or agents that stimulate wound healing in the upper respiatorio tract and / or in the ear.
DE19842753A1 (en) 1998-09-18 2000-03-23 Bayer Ag Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose
DE19842914A1 (en) * 1998-09-18 2000-03-23 Basf Ag Test system for the characterization of the compatibility of biologically active substances and polyvinylpyrrolidone
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
UA73101C2 (en) * 1998-12-16 2001-09-17 Aventic Pharmaceuticals Inc Antagonist of serotonin receptor encapsulated by biodegradable polymer and method for its manufacture
US6455526B1 (en) 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
DE60039377D1 (en) 1999-02-09 2008-08-21 Pfizer Prod Inc Compositions of basic drugs with improved bioavailability
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
ES2274372T3 (en) 1999-05-27 2007-05-16 Euro-Celtique S.A. Antiseptics use in the manufacture of a pharmaceutical preparation for preventing or treating inflammation within the human body.
DE19945982A1 (en) * 1999-09-24 2001-03-29 Knoll Ag Certain speed particles
DE19949897A1 (en) * 1999-10-15 2001-04-19 Rainer Rogasch Shaped article, e.g. in stick form, for controlled release of drugs in wounds or body cavities, comprising hydrophilic outer phase, lipophilic inner phase and drug, e.g. antibiotic
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AT329579T (en) 1999-11-12 2006-07-15 Abbott Lab Solid dispersion with ritonavir, fenofibrate or griseofulvin
CZ20022047A3 (en) * 1999-12-23 2003-09-17 Pfizer Products Inc. Pharmaceutical compositions providing increased concentration of a medicament
EP1283040A4 (en) * 2000-03-21 2008-05-14 Nippon Shinyaku Co Ltd Sustained release oral preparations
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying drug formulation and use of this formulation
DE10031044A1 (en) 2000-06-26 2002-01-03 Bayer Ag Endoparasiticidal compositions for voluntary oral ingestion by animals
AU7105501A (en) * 2000-07-17 2002-01-30 Yamanouchi Pharma Co Ltd Pharmaceutical composition improved in peroral absorbability
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AR038375A1 (en) * 2002-02-01 2005-01-12 Pfizer Prod Inc Pharmaceutical compositions inhibitors transfer protein cholesteryl esters
EP1323416B1 (en) * 2000-09-25 2010-12-22 Nippon Shinyaku Co., Ltd. Process for producing medicinal solid dispersion
KR100960200B1 (en) 2000-10-30 2010-05-27 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
ITMI20010141A1 (en) * 2001-01-26 2002-07-26 Giuliani Spa A process for the preparation of pharmaceutical or dietary compositions for the delivery of labile substances in the intestine
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
JP3548566B2 (en) * 2001-02-27 2004-07-28 アストラゼネカ アクチボラグ Pharmaceutical preparations
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
AU2002303614B2 (en) 2001-05-02 2005-02-10 Euro-Celtique S.A. Once-a-day oxycodone formulations
AT361758T (en) * 2001-06-22 2007-06-15 Pfizer Prod Inc Pharmaceutical compositions comprising a solid dispersion of a sparingly soluble in water drug and a polymer löslichkeitsteigerndes
EA200301250A1 (en) * 2001-06-22 2004-06-24 Пфайзер Продактс Инк. PHARMACEUTICAL COMPOSITIONS, CONTAINING LOW-Soluble And / Or Acid-Sensitive Drugs and Neutralized Acid Polymers
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
JP2004534812A (en) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク The pharmaceutical composition of the dispersion of drug and neutral polymer
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
SE0103424D0 (en) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
US7491407B2 (en) * 2001-10-31 2009-02-17 North Carolina State University Fiber-based nano drug delivery systems (NDDS)
EP1474144B1 (en) * 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
BR0307333A (en) 2002-02-01 2004-12-07 Pfizer Prod Inc Methods for the preparation of homogenous dispersions of solid amorphous drug atomized using a spray drying system
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
CA2496441C (en) * 2002-08-12 2010-03-16 Pfizer Products Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
DE60331873D1 (en) 2002-12-20 2010-05-06 Pfizer Prod Inc Dosage form containing a CETP inhibitor and an HMG-CoA reductase inhibitor
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
US8486447B2 (en) * 2003-02-03 2013-07-16 Novartis Ag Pharmaceutical formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
KR20060096076A (en) * 2003-11-14 2006-09-05 화이자 프로덕츠 인크. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
EP1694657A1 (en) * 2003-12-09 2006-08-30 Pfizer Inc. Compositions comprising an hiv protease inhibitor
AU2005214159A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
US20050238721A1 (en) * 2004-04-07 2005-10-27 Acquarulo Lawrence A Jr One step compounding extrusion of drug filled polymers
EP1750669A1 (en) * 2004-05-04 2007-02-14 Boehringer Ingelheim International Gmbh Solid pharmaceutical form comprising an ltb4 antagonist
CN1950374A (en) 2004-05-25 2007-04-18 辉瑞产品公司 Tetraazabenzo[e]azulene derivatives and analogs thereof
WO2005115330A2 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
HN2005000484A (en) * 2004-08-27 2010-06-08 Bayer Healthcare Llc New pharmaceutical compositions for the treatment of hyperproliferative disorders
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN101443006B (en) 2004-12-31 2012-10-10 雷迪美国治疗股份有限公司 Novel benzylamine derivatives as CETP inhibitors
US8617604B2 (en) 2005-02-03 2013-12-31 Bend Research, Inc. Pharmaceutical compositions with enhanced performance
EP1690528A1 (en) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent
BRPI0614197A2 (en) * 2005-08-02 2012-11-20 Drossapharm Ag composiÇço, administraÇço forms, the process for preparaÇço composiÇço, indomethacin and acemetacin active ingredients, and the use composiÇço
AU2006294581B2 (en) 2005-09-27 2011-11-03 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
EP1832281A1 (en) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Process for producing a solid dispersion of an active ingredient
US20080090897A1 (en) 2006-08-11 2008-04-17 The Johns Hopkins University Compositions and methods for neuroprotectin
PL2530083T3 (en) 2006-09-22 2016-11-30 Inhibitors of bruton's tyrosine kinase
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
US7607596B1 (en) 2007-03-07 2009-10-27 Exxpharma, LLC Process for enhancing the solubility of poorly soluble drugs
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2008149192A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
JP2010533729A (en) 2007-07-17 2010-10-28 プレキシコン,インコーポレーテッド Compounds and methods for kinase modulation, and adaptive for the
CA2693169C (en) 2007-07-19 2016-01-12 Metabolex, Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
WO2009026461A2 (en) * 2007-08-21 2009-02-26 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
WO2009035818A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
JPWO2009038112A1 (en) * 2007-09-21 2011-01-06 塩野義製薬株式会社 Solid preparation containing Npyy5 receptor antagonists
AU2008303129B2 (en) 2007-09-25 2013-08-01 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
FR2922100B1 (en) * 2007-10-11 2009-12-11 Oreal semisolids method for preparing particles for cosmetic interest
WO2009053635A1 (en) * 2007-10-11 2009-04-30 L'oreal Structured cosmetic composition
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20090270404A1 (en) * 2008-03-31 2009-10-29 Metabolex, Inc. Oxymethylene aryl compounds and uses thereof
EP2321303A4 (en) 2008-08-27 2011-11-16 Calcimedica Inc Compounds that modulate intracellular calcium
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
ES2552087T3 (en) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal CYP17 inhibitors / antiandrogens
CN105237530A (en) 2009-04-03 2016-01-13 豪夫迈罗氏公司 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
RU2012101214A (en) 2009-06-16 2013-07-27 Пфайзер Инк. The dosage forms of apixaban
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
KR101837927B1 (en) * 2010-03-26 2018-03-13 다우 글로벌 테크놀로지스 엘엘씨 Melt-extruded film
CN102821754B (en) * 2010-03-26 2014-06-18 陶氏环球技术有限责任公司 Multilayer melt-extruded film
CN102892815B (en) * 2010-03-26 2016-05-18 陶氏环球技术有限责任公司 The melt extruded film
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
PT2563776T (en) 2010-04-27 2016-09-19 Calcimedica Inc Compounds that modulate intracellular calcium
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
BR112012032248A2 (en) * 2010-06-23 2016-09-13 Metabolex Inc 5-ethyl-2- compositions {4 - [- 4- (4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} pyrimidine
US20120172831A1 (en) 2010-07-02 2012-07-05 Trevor John Darcy Methods of Delivering a Health Care Active by Administering Personal Health Care Articles Comprising a Filament
CN103180316A (en) 2010-08-27 2013-06-26 钙医学公司 Compounds that modulate intracellular calciu
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2824639A1 (en) 2011-02-17 2012-08-23 Ashish Chatterji A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion
TWI558702B (en) 2011-02-21 2016-11-21 Plexxikon Inc Solid forms of a pharmaceutically active substance
DE102011015370A1 (en) * 2011-03-29 2012-10-04 Emodys Gmbh Preparing a matrix comprises preparing a mixture containing an active agent and a biopolymer e.g. alginate, gum arabic, locust bean gum, karaya gum, tara gum or tragacanth and extruding the obtained mixture
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
KR101774223B1 (en) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
UA110853C2 (en) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Dosage forms histone deacetylase inhibitor in combination with bendamustine and their use
KR101803866B1 (en) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 5-benzylaminomethyl-6-aminopyrazolo[3,4-b]pyridine derivatives as cholesteryl ester-transfer protein(cetp) inhibitors useful for the treatment of atherosclerosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
IN2012DE00674A (en) 2012-03-07 2015-08-21 National Institute Of Pharmaceutical Education And Research (Niper) novel one step process for preparation of compositions comprising nanocrystalline solid dispersions
AP201407953A0 (en) 2012-04-06 2014-09-30 Pfizer Diacylglycerol acyltransferase 2 inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CA2878163A1 (en) 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
EP2900674B1 (en) 2012-09-28 2017-05-31 University of Washington through its Center for Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20140059146A (en) 2012-11-07 2014-05-15 에스케이바이오팜 주식회사 Solid dispersions of insoluble drug and preparation method therof
RU2015123632A (en) 2012-11-19 2017-01-10 Др. Редди'С Лабораторис Лтд. The pharmaceutical compositions of CETP inhibitors
JP6150518B2 (en) 2012-12-27 2017-06-21 花王株式会社 Method for producing a polyphenol composition
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
MX2015012274A (en) 2013-03-14 2016-06-02 Univ Maryland Androgen receptor down-regulating agents and uses thereof.
WO2015023710A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9296882B2 (en) 2013-09-04 2016-03-29 Zzyzx Polymers LLC Methods for increasing throughput rates of solid-state extrusion devices
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054595A1 (en) * 2013-10-12 2015-04-16 Zzyzx Polymers LLC Fabricating drug delivery systems
WO2015084998A1 (en) 2013-12-05 2015-06-11 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US9962363B2 (en) 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
CN106103425A (en) 2014-03-17 2016-11-09 辉瑞公司 Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
CN106232144A (en) 2014-03-18 2016-12-14 武田药品工业株式会社 Solid dispersion
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (en) 2014-06-03 2016-02-01 Tissue Tech Inc Compositions and methods
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
EP3253766A4 (en) 2015-02-06 2018-07-25 University of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
EP3297645A4 (en) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
RU2017144574A (en) 2015-05-28 2019-06-28 Др. Редди'С Лабораториз Лтд. Celecoxib oral composition for the treatment of pain
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US20170209462A1 (en) 2015-08-31 2017-07-27 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
EA201891440A1 (en) 2016-01-19 2018-12-28 Янссен Фармацевтика Нв Compositions / compositions containing btk inhibitor
MX2018008772A (en) 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor.
JP2019510826A (en) 2016-04-04 2019-04-18 シノピア バイオサイエンシーズ,インク. Treatment of extrapyramidal syndrome using trapidil
CN109069652A (en) 2016-05-13 2018-12-21 默克专利股份有限公司 The granularity and distribution of polymer for melt extrusion application
KR20190006992A (en) 2016-05-13 2019-01-21 메르크 파텐트 게엠베하 Amino sugars for use as a plasticizer
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (en) 2016-08-19 2018-11-07 Pfizer Diacylglycerol acyltransferase 2 inhibitors
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018083113A1 (en) 2016-11-07 2018-05-11 Merck Patent Gmbh Instant release capsule based on hot melt extruded polyvinyl alcohol
CA3042770A1 (en) 2016-11-07 2018-05-11 Merck Patent Gmbh Anti-alcohol-induced dose dumping tablet based on polyvinyl alcohol
AU2017352556A1 (en) 2016-11-07 2019-06-20 Merck Patent Gmbh Controlled release tablet based on polyvinyl alcohol and its manufacturing
WO2018163066A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1504553A (en) * 1975-11-17 1978-03-22 Sandoz Ltd Tablet formulations
JPS5257315A (en) * 1975-11-04 1977-05-11 Sandoz Ag Tablet for medical preparation
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
JPH031288B2 (en) * 1980-11-14 1991-01-10 Kanebo Ltd
JPH0220610B2 (en) * 1981-12-23 1990-05-10 Shionogi & Co
JPS6240277A (en) * 1985-08-15 1987-02-21 Ajinomoto Co Inc Production of granular food
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
DE3612211A1 (en) * 1986-04-11 1987-10-15 Basf Ag Continuous method for tableting
DE3612212A1 (en) * 1986-04-11 1987-10-15 Basf Ag shaping process for the preparation of solid pharmaceutical
US4760094A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4842761A (en) * 1988-03-23 1989-06-27 International Flavors & Fragrances, Inc. Compositions and methods for controlled release of fragrance-bearing substances
DE3812567A1 (en) 1988-04-15 1989-10-26 Basf Ag A process for preparing pharmaceutical mixtures
DE3827061C1 (en) * 1988-08-10 1990-02-15 Deutsche Gelatine-Fabriken Stoess & Co Gmbh, 6930 Eberbach, De
DE3830353A1 (en) * 1988-09-07 1990-03-15 Basf Ag shaping process for the continuous preparation of solid pharmaceutical
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix dosage
NZ231281A (en) * 1988-11-08 1991-01-29 Takeda Chemical Industries Ltd Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol
IL92343D0 (en) * 1988-12-20 1990-07-26 Gist Brocades Nv Granulate for multiparticulate controlled release oral compositions,their preparation and oral pharmaceutical compositions containing them
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
FR2670398B1 (en) * 1990-12-14 1995-02-17 Roquette Freres directly compressible pulverulent composition and obtaining METHOD.
AU671811B2 (en) * 1991-12-18 1996-09-12 Warner-Lambert Company A process for the preparation of a solid dispersion
JP2616252B2 (en) * 1992-10-16 1997-06-04 日本新薬株式会社 Preparation of the wax matrix
EP1275437B1 (en) * 1994-09-21 2007-03-21 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Use of an adsorbent for interleukins, process for removing the same
DE19509807A1 (en) * 1995-03-21 1996-09-26 Basf Ag A process for the preparation of drug formulations in the form of a solid solution of the active ingredient in a polymer matrix, with this method produced active substance preparations
HN1998000115A (en) * 1997-08-21 1999-06-02 Warner Lambert Co Dosificacin forms farmacuticas slidas
US5954175A (en) * 1997-09-02 1999-09-21 Northrop Grumman Corporation Modularized parallel drivetrain
EP0966269A1 (en) * 1997-10-07 1999-12-29 Fuiz Technologies Ltd. Immediate release drug delivery forms
US6029764A (en) * 1997-11-12 2000-02-29 Case Corporation Coordinated control of an active suspension system for a work vehicle
DE60039377D1 (en) * 1999-02-09 2008-08-21 Pfizer Prod Inc Compositions of basic drugs with improved bioavailability
DE60042352D1 (en) * 1999-02-10 2009-07-23 Pfizer Prod Inc contain osmotic system for the administration of active substances, the solid amorphous dispersions
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions

Also Published As

Publication number Publication date
DK0580860T3 (en) 1998-05-25
KR182801B1 (en) 1999-05-01
ES2111065T3 (en) 1998-03-01
GR3025864T3 (en) 1998-04-30
CA2108575A1 (en) 1992-10-17
DE69222847T3 (en) 2005-09-15
EP0580860A1 (en) 1994-02-02
JP2527107B2 (en) 1996-08-21
DK580860T4 (en)
DK580860T3 (en)
DK0580860T4 (en) 2005-03-21
DE69222847D1 (en) 1997-11-27
EP0580860B2 (en) 2004-12-15
CA2108575C (en) 2002-10-22
DE69222847T2 (en) 1998-05-20
ES2111065T5 (en) 2005-06-16
EP0580860A4 (en) 1994-06-15
EP0580860B1 (en) 1997-10-22
US5456923A (en) 1995-10-10
AU1537292A (en) 1992-11-17
WO1992018106A1 (en) 1992-10-29

Similar Documents

Publication Publication Date Title
DE69217564D1 (en) A process for preparing Additionspolymersiationskatalysatoren via Metalzentraoxidation
DE69334213D1 (en) A process for preparing fluoropolymers
DE69032773T2 (en) A process for producing a semiconductor device
DE69305663D1 (en) A process for preparing Metallcyankatalysekomplexen
DE69332291D1 (en) A process for preparing wachsmatrizes
DE69130485T2 (en) A process for producing a fiber-reinforced plasterboard
DE69430754D1 (en) A process for preparing an acrylate
DE69327527D1 (en) A process for producing a multi-phase composition
AT183982T (en) A process for producing a discharge
DE69333614D1 (en) A process for preparing Polyisobutenylhydroxyaromaten
DE69332383D1 (en) A process for producing a contact lens
DE69225425D1 (en) A process for preparing Polyätheramideblockpolymeren
DE69222979D1 (en) A process for producing microlenses
DE69229154T2 (en) A process for preparing naphtha
DE69220239T2 (en) A process for preparing an aqueous dispersion
DE69619691D1 (en) A process for producing a diffraction structure
AT190835T (en) A process for producing surface-modified nanoparticles antikrebsmittel-
DE59107392D1 (en) A process for producing a multi-layer paint
DE69232432T2 (en) A process for producing a semiconductor device
DE69227391D1 (en) A process for producing solid objects
DE69228640T2 (en) A process for producing L-threonine
DE69231803D1 (en) A process for producing a semiconductor device
DE69301963T2 (en) A process for producing a high voltage line
DE69308529T3 (en) A process for producing a milk composition
DE69303879D1 (en) A process for producing N4-acyl-5'-deoxy-5-fluorocytidinderivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0580860

Country of ref document: EP